Cerebrospinal fluid sTREM2 levels are associated with gray matter volume increases and reduced diffusivity in early Alzheimer's disease

Alzheimer's and Dementia

Volumn 12, Issue 12, 2016, Pages 1259-1272

  Gispert, Juan Domingo ^a,b,c   Suárez Calvet, Marc ^d,e   Monté, Gemma C ^f   Tucholka, Alan ^a   Falcon, Carles ^a,b   Rojas, Santiago ^a,g   Rami, Lorena ^f   Sánchez Valle, Raquel ^f   Lladó, Albert ^f   Kleinberger, Gernot ^d,h   Haass, Christian ^d,e,h   Molinuevo, José Luis ^a,f  

^a Barcelonaßeta Brain Research Center   (Spain)

^b BIOMATERIALES Y NANOMEDICINA CIBER BBN   (Spain)

^c UNIVERSITAT POMPEU FABRA   (Spain)

^d UNIVERSITY OF MUNICH   (Germany)

^e GERMAN CENTER FOR NEURODEGENERATIVE DISEASES DZNE   (Germany)

^f HOSPITAL CLÍNIC   (Spain)

^g UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^h Germany 3 Munich Cluster for Systems Neurology   (Germany)

Author keywords

Alzheimer's disease; Biomarkers; Cerebrospinal fluid; Neuroinflammation; TREM2

Indexed keywords

TAU PROTEIN; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2; WATER; AMYLOID BETA PROTEIN; BIOLOGICAL MARKER;

ADULT; AGE; AGED; ALZHEIMER DISEASE; ANGULAR GYRUS; ANISOTROPY; ARTICLE; BRAIN CORTEX; BRAIN SIZE; CEREBROSPINAL FLUID; CLINICAL FEATURE; CONTROLLED STUDY; DIFFUSION WEIGHTED IMAGING; DISEASE ASSOCIATION; FEMALE; GRAY MATTER; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MILD COGNITIVE IMPAIRMENT; NERVOUS SYSTEM INFLAMMATION; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PRECUNEUS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CEREBROSPINAL FLUID LEVEL; SEX; SUPRAMARGINAL GYRUS; COGNITIVE DEFECT; DIAGNOSTIC IMAGING; INFLAMMATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY;

AGED; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; BIOMARKERS; COGNITIVE DYSFUNCTION; FEMALE; GRAY MATTER; HUMANS; INFLAMMATION; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; TAU PROTEINS;

EID: 84992068717     PISSN: 15525260     EISSN: 15525279     Source Type: Journal    
DOI: 10.1016/j.jalz.2016.06.005     Document Type: Article

References (65)

1. [1] Dubois, B., Feldman, H.H., Jacova, C., Hampel, H., Molinuevo, J.L., Blennow, K., et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol 13 (2014), 614–629.
2. [2] Albert, M.S., DeKosky, S.T., Dickson, D., Dubois, B., Feldman, H.H., Fox, N.C., et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7 (2011), 270–279.
3. [3] Sperling, R.A., Aisen, P.S., Beckett, L.A., Bennett, D.A., Craft, S., Fagan, A.M., et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7 (2011), 280–292.
4. [4] Dubois, B., Picard, G., Sarazin, M., Early detection of Alzheimer's disease: new diagnostic criteria. Dialogues Clin Neurosci 11 (2009), 135–139.
5. [5] Heneka, M.T., Carson, M.J., El Khoury, J., Landreth, G.E., Brosseron, F., Feinstein, D.L., et al. Neuroinflammation in Alzheimer's disease. Lancet Neurol 14 (2015), 388–405.
6. [6] Eikelenboom, P., Veerhuis, R., van Exel, E., Hoozemans, J.J., Rozemuller, A.J., van Gool, W.A., The early involvement of the innate immunity in the pathogenesis of late-onset Alzheimer's disease: neuropathological, epidemiological and genetic evidence. Curr Alzheimer Res 8 (2011), 142–150.
7. [7] Daws, M.R., Lanier, L.L., Seaman, W.E., Ryan, J.C., Cloning and characterization of a novel mouse myeloid DAP12-associated receptor family. Eur J Immunol 31 (2001), 783–791.
8. [8] Colonna, M., TREMs in the immune system and beyond. Nat Rev Immunol 3 (2003), 445–453.
9. [9] Bouchon, A., Hernandez-Munain, C., Cella, M., Colonna, M., A DAP12-mediated pathway regulates expression of CC chemokine receptor 7 and maturation of human dendritic cells. J Exp Med 194 (2001), 1111–1122.
10. [10] Paloneva, J., Mandelin, J., Kiialainen, A., Bohling, T., Prudlo, J., Hakola, P., et al. DAP12/TREM2 deficiency results in impaired osteoclast differentiation and osteoporotic features. J Exp Med 198 (2003), 669–675.
11. [11] Schmid, C.D., Sautkulis, L.N., Danielson, P.E., Cooper, J., Hasel, K.W., Hilbush, B.S., et al. Heterogeneous expression of the triggering receptor expressed on myeloid cells-2 on adult murine microglia. J Neurochem 83 (2002), 1309–1320.
12. [12] Frank, S., Burbach, G.J., Bonin, M., Walter, M., Streit, W., Bechmann, I., et al. TREM2 is upregulated in amyloid plaque-associated microglia in aged APP23 transgenic mice. Glia 56 (2008), 1438–1447.
13. [13] Hickman, S.E., El Khoury, J., TREM2 and the neuroimmunology of Alzheimer's disease. Biochem Pharmacol 88 (2014), 495–498.
14. [14] Daws, M.R., Sullam, P.M., Niemi, E.C., Chen, T.T., Tchao, N.K., Seaman, W.E., Pattern recognition by TREM-2: binding of anionic ligands. J Immunol 171 (2003), 594–599.
15. [15] Hsieh, C.L., Koike, M., Spusta, S.C., Niemi, E.C., Yenari, M., Nakamura, M.C., et al. A role for TREM2 ligands in the phagocytosis of apoptotic neuronal cells by microglia. J Neurochem 109 (2009), 1144–1156.
16. [16] N'Diaye, E.N., Branda, C.S., Branda, S.S., Nevarez, L., Colonna, M., Lowell, C., et al. TREM-2 (triggering receptor expressed on myeloid cells 2) is a phagocytic receptor for bacteria. J Cell Biol 184 (2009), 215–223.
17. [17] Stuart, J.M., Segal, E., Koller, D., Kim, S.K., A gene-coexpression network for global discovery of conserved genetic modules. Science 302 (2003), 249–255.
18. [18] Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., et al. TREM2 variants in Alzheimer's disease. N Engl J Med 368 (2013), 117–127.
19. [19] Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P.V., Snaedal, J., et al. Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med 368 (2013), 107–116.
20. [20] Rajagopalan, P., Hibar, D.P., Thompson, P.M., TREM2 and neurodegenerative disease. N Engl J Med 369 (2013), 1565–1567.
21. [21] Cady, J., Koval, E.D., Benitez, B.A., Zaidman, C., Jockel-Balsarotti, J., Allred, P., et al. TREM2 variant p.R47H as a risk factor for sporadic amyotrophic lateral sclerosis. JAMA Neurol 71 (2014), 449–453.
22. [22] Rayaprolu, S., Mullen, B., Baker, M., Lynch, T., Finger, E., Seeley, W.W., et al. TREM2 in neurodegeneration: evidence for association of the p.R47H variant with frontotemporal dementia and Parkinson's disease. Mol Neurodegener, 8, 2013, 19.
23. [23] Borroni, B., Ferrari, F., Galimberti, D., Nacmias, B., Barone, C., Bagnoli, S., et al. Heterozygous TREM2 mutations in frontotemporal dementia. Neurobiol Aging 35 (2014), 934.e7–934.e10.
24. [24] Cuyvers, E., Bettens, K., Philtjens, S., Van Langenhove, T., Gijselinck, I., van der Zee, J., et al. Investigating the role of rare heterozygous TREM2 variants in Alzheimer's disease and frontotemporal dementia. Neurobiol Aging 35 (2014), 726.e11–726.e19.
25. [25] Guerreiro, R., Bilgic, B., Guven, G., Bras, J., Rohrer, J., Lohmann, E., et al. Novel compound heterozygous mutation in TREM2 found in a Turkish frontotemporal dementia-like family. Neurobiol Aging 34 (2013), 2890.e1–2890.e5.
26. [26] Paloneva, J., Manninen, T., Christman, G., Hovanes, K., Mandelin, J., Adolfsson, R., et al. Mutations in two genes encoding different subunits of a receptor signaling complex result in an identical disease phenotype. Am J Hum Genet 71 (2002), 656–662.
27. [27] Kleinberger, G., Yamanishi, Y., Suarez-Calvet, M., Czirr, E., Lohmann, E., Cuyvers, E., et al. TREM2 mutations implicated in neurodegeneration impair cell surface transport and phagocytosis. Sci Transl Med, 6, 2014, 243ra86.
28. [28] Wunderlich, P., Glebov, K., Kemmerling, N., Tien, N.T., Neumann, H., Walter, J., Sequential proteolytic processing of the triggering receptor expressed on myeloid cells-2 (TREM2) protein by ectodomain shedding and gamma-secretase-dependent intramembranous cleavage. J Biol Chem 288 (2013), 33027–33036.
29. [29] Piccio, L., Buonsanti, C., Cella, M., Tassi, I., Schmidt, R.E., Fenoglio, C., et al. Identification of soluble TREM-2 in the cerebrospinal fluid and its association with multiple sclerosis and CNS inflammation. Brain 131:Pt 11 (2008), 3081–3091.
30. [30] Piccio, L., Deming, Y., Del-Aguila, J.L., Ghezzi, L., Holtzman, D.M., Fagan, A.M., et al. Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status. Acta Neuropathol 131 (2016), 925–933.
31. [31] Heslegrave, A., Heywood, W., Paterson, R., Magdalinou, N., Svensson, J., Johansson, P., et al. Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer's disease. Mol Neurodegener, 11, 2016, 3.
32. [32] Suarez-Calvet, M., Kleinberger, G., Araque Caballero, M.A., Brendel, M., Rominger, A., Alcolea, D., et al. sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers. EMBO Mol Med 8 (2016), 466–476.
33. [33] Stricker, N.H., Dodge, H.H., Dowling, N.M., Han, S.D., Erosheva, E.A., Jagust, W.J., CSF biomarker associations with change in hippocampal volume and precuneus thickness: implications for the Alzheimer's pathological cascade. Brain Imaging Behav 6 (2012), 599–609.
34. [34] Blennow, K., Zetterberg, H., The application of cerebrospinal fluid biomarkers in early diagnosis of Alzheimer disease. Med Clin North Am 97 (2013), 369–376.
35. [35] Bonneh-Barkay, D., Wang, G., Starkey, A., Hamilton, R.L., Wiley, C.A., In vivo CHI3L1 (YKL-40) expression in astrocytes in acute and chronic neurological diseases. J Neuroinflammation, 7, 2010, 34.
36. [36] Craig-Schapiro, R., Perrin, R.J., Roe, C.M., Xiong, C., Carter, D., Cairns, N.J., et al. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. Biol Psychiatry 68 (2010), 903–912.
37. [37] Alcolea, D., Vilaplana, E., Pegueroles, J., Montal, V., Sanchez-Juan, P., Gonzalez-Suarez, A., et al. Relationship between cortical thickness and cerebrospinal fluid YKL-40 in predementia stages of Alzheimer's disease. Neurobiol Aging 36 (2015), 2018–2023.
38. [38] Gispert, J.D., Monté, G.C., Falcon, C., Tucholka, A., Rojas, S., Sanchez-Valle, R., et al. CSF YKL-40 and pTau181 are related to different cerebral morphometric patterns in early AD. Neurobiol Aging 38 (2016), 47–55.
39. [39] Gass, A., Niendorf, T., Hirsch, J.G., Acute and chronic changes of the apparent diffusion coefficient in neurological disorders–biophysical mechanisms and possible underlying histopathology. J Neurol Sci 186 Suppl 1 (2001), S15–S23.
40. [40] Sexton, C.E., Kalu, U.G., Filippini, N., Mackay, C.E., Ebmeier, K.P., A meta-analysis of diffusion tensor imaging in mild cognitive impairment and Alzheimer's disease. Neurobiol Aging, 32, 2011 2322.e5–18.
41. [41] Acosta-Cabronero, J., Alley, S., Williams, G.B., Pengas, G., Nestor, P.J., Diffusion tensor metrics as biomarkers in Alzheimer's disease. PLoS One, 7, 2012, e49072.
42. [42] Amlien, I.K., Fjell, A.M., Walhovd, K.B., Selnes, P., Stenset, V., Grambaite, R., et al. Mild cognitive impairment: cerebrospinal fluid tau biomarker pathologic levels and longitudinal changes in white matter integrity. Radiology 266 (2013), 295–303.
43. [43] Bosch, B., Arenaza-Urquijo, E.M., Rami, L., Sala-Llonch, R., Junque, C., Sole-Padulles, C., et al. Multiple DTI index analysis in normal aging, amnestic MCI and AD. Relationship with neuropsychological performance. Neurobiol Aging 33 (2012), 61–74.
44. [44] Kantarci, K., Schwarz, C.G., Reid, R.I., Przybelski, S.A., Lesnick, T.G., Zuk, S.M., et al. White matter integrity determined with diffusion tensor imaging in older adults without dementia: influence of amyloid load and neurodegeneration. JAMA Neurol 71 (2014), 1547–1554.
45. [45] Molinuevo, J.L., Ripolles, P., Simo, M., Llado, A., Olives, J., Balasa, M., et al. White matter changes in preclinical Alzheimer's disease: a magnetic resonance imaging-diffusion tensor imaging study on cognitively normal older people with positive amyloid beta protein 42 levels. Neurobiol Aging 35 (2014), 2671–2680.
46. [46] Antonell, A., Fortea, J., Rami, L., Bosch, B., Balasa, M., Sanchez-Valle, R., et al. Different profiles of Alzheimer's disease cerebrospinal fluid biomarkers in controls and subjects with subjective memory complaints. J Neural Transm 118 (2011), 259–262.
47. [47] Jack, C.R. Jr., Albert, M.S., Knopman, D.S., McKhann, G.M., Sperling, R.A., Carrillo, M.C., et al. Introduction to the recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7 (2011), 257–262.
48. [48] Molinuevo, J.L., Gispert, J.D., Dubois, B., Heneka, M.T., Lleo, A., Engelborghs, S., et al. The AD-CSF-index discriminates Alzheimer's disease patients from healthy controls: a validation study. J Alzheimers Dis 36 (2013), 67–77.
49. [49] McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., Stadlan, E.M., Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34 (1984), 939–944.
50. [50] Jenkinson, M., Beckmann, C.F., Behrens, T.E., Woolrich, M.W., Smith, S.M., FSL. Neuroimage 62 (2012), 782–790.
51. [51] Manjon, J.V., Coupe, P., Concha, L., Buades, A., Collins, D.L., Robles, M., Diffusion weighted image denoising using overcomplete local PCA. PLoS One, 8, 2013, e73021.
52. [52] Wiest-Daessle, N., Prima, S., Coupe, P., Morrissey, S.P., Barillot, C., Rician noise removal by non-Local Means filtering for low signal-to-noise ratio MRI: applications to DT-MRI. Med Image Comput Comput Assist Interv 11:Pt 2 (2008), 171–179.
53. [53] Tustison, N.J., Avants, B.B., Cook, P.A., Zheng, Y., Egan, A., Yushkevich, P.A., et al. N4ITK: improved N3 bias correction. IEEE Trans Med Imaging 29 (2010), 1310–1320.
54. [54] Avants, B.B., Tustison, N.J., Song, G., Cook, P.A., Klein, A., Gee, J.C., A reproducible evaluation of ANTs similarity metric performance in brain image registration. Neuroimage 54 (2011), 2033–2044.
55. [55] Nusbaum, A.O., Tang, C.Y., Buchsbaum, M.S., Wei, T.C., Atlas, S.W., Regional and global changes in cerebral diffusion with normal aging. AJNR Am J Neuroradiol 22 (2001), 136–142.
56. [56] Moseley, M., Diffusion tensor imaging and aging - a review. NMR Biomed 15 (2002), 553–560.
57. [57] Tarawneh, R., Head, D., Allison, S., Buckles, V., Fagan, A.M., Ladenson, J.H., et al. Cerebrospinal Fluid Markers of Neurodegeneration and Rates of Brain Atrophy in Early Alzheimer Disease. JAMA Neurol 72 (2015), 656–665.
58. [58] Johnson, K.A., Schultz, A., Betensky, R.A., Becker, J.A., Sepulcre, J., Rentz, D., et al. Tau PET imaging in aging and early Alzheimer's disease. Ann Neurol 79 (2016), 110–119.
59. [59] Lue, L.F., Schmitz, C.T., Serrano, G., Sue, L.I., Beach, T.G., Walker, D.G., TREM2 Protein Expression Changes Correlate with Alzheimer's Disease Neurodegenerative Pathologies in Post-Mortem Temporal Cortices. Brain Pathol 25 (2015), 469–480.
60. [60] Yasuno, F., Kosaka, J., Ota, M., Higuchi, M., Ito, H., Fujimura, Y., et al. Increased binding of peripheral benzodiazepine receptor in mild cognitive impairment-dementia converters measured by positron emission tomography with [(1)(1)C]DAA1106. Psychiatry Res 203 (2012), 67–74.
61. [61] Wang, Y., Cella, M., Mallinson, K., Ulrich, J.D., Young, K.L., Robinette, M.L., et al. TREM2 lipid sensing sustains the microglial response in an Alzheimer's disease model. Cell 160 (2015), 1061–1071.
62. [62] Luis, E.O., Ortega-Cubero, S., Lamet, I., Razquin, C., Cruchaga, C., Benitez, B.A., et al. Frontobasal gray matter loss is associated with the TREM2 p.R47H variant. Neurobiol Aging 35 (2014), 2681–2690.
63. [63] Alexander, A.L., Lee, J.E., Lazar, M., Field, A.S., Diffusion tensor imaging of the brain. Neurotherapeutics 4 (2007), 316–329.
64. [64] Ohrfelt, A., Axelsson, M., Malmestrom, C., Novakova, L., Heslegrave, A., Blennow, K., et al. Soluble TREM-2 in cerebrospinal fluid from patients with multiple sclerosis treated with natalizumab or mitoxantrone. Mult Scler, 2016 [Epub ahead of print].
65. [65] Rosenblum, W.I., Cytotoxic edema: monitoring its magnitude and contribution to brain swelling. J Neuropathol Exp Neurol 66 (2007), 771–778.